Literature DB >> 28300564

Contrasting roles of the ABCG2 Q141K variant in prostate cancer.

Kathryn M Sobek1, Jessica L Cummings2, Dean J Bacich3, Denise S O'Keefe4.   

Abstract

ABCG2 is a membrane transport protein that effluxes growth-promoting molecules, such as folates and dihydrotestosterone, as well as chemotherapeutic agents. Therefore it is important to determine how variants of ABCG2 affect the transporter function in order to determine whether modified treatment regimens may be necessary for patients harboring ABCG2 variants. Previous studies have demonstrated an association between the ABCG2 Q141K variant and overall survival after a prostate cancer diagnosis. We report here that in patients with recurrent prostate cancer, those who carry the ABCG2 Q141K variant had a significantly shorter time to PSA recurrence post-prostatectomy than patients homozygous for wild-type ABCG2 (P=0.01). Transport studies showed that wild-type ABCG2 was able to efflux more folic acid than the Q141K variant (P<0.002), suggesting that retained tumoral folate contributes to the decreased time to PSA recurrence in the Q141K variant patients. In a seemingly conflicting study, it was previously reported that docetaxel-treated Q141K variant prostate cancer patients have a longer survival time. We found this may be due to less efficient docetaxel efflux in cells with the Q141K variant versus wild-type ABCG2. In human prostate cancer tissues, confocal microscopy revealed that all genotypes had a mixture of cytoplasmic and plasma membrane staining, with noticeably less staining in the two homozygous KK patients. In conclusion, the Q141K variant plays contrasting roles in prostate cancer: 1) by decreasing folate efflux, increased intracellular folate levels result in enhanced tumor cell proliferation and therefore time to recurrence decreases; and 2) in patients treated with docetaxel, by decreasing its efflux, intratumoral docetaxel levels and tumor cell drug sensitivity increase and therefore patient survival time increases. Taken together, these data suggest that a patient's ABCG2 genotype may be important when determining a personalized treatment plan.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ABCG2; Docetaxel; Folate; Prostate cancer; Q141K variant

Mesh:

Substances:

Year:  2017        PMID: 28300564      PMCID: PMC5424544          DOI: 10.1016/j.yexcr.2017.03.020

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  36 in total

1.  Single nucleotide polymorphisms modify the transporter activity of ABCG2.

Authors:  Kuniaki Morisaki; Robert W Robey; Csilla Ozvegy-Laczka; Yasumasa Honjo; Orsolya Polgar; Kenneth Steadman; Balázs Sarkadi; Susan E Bates
Journal:  Cancer Chemother Pharmacol       Date:  2005-04-19       Impact factor: 3.333

2.  The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.

Authors:  Pauline Breedveld; Dick Pluim; Greta Cipriani; Femke Dahlhaus; Maria A J van Eijndhoven; Cornelia J F de Wolf; Annemieke Kuil; Jos H Beijnen; George L Scheffer; Gerrit Jansen; Piet Borst; Jan H M Schellens
Journal:  Mol Pharmacol       Date:  2006-10-10       Impact factor: 4.436

3.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

Review 4.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.

Authors:  M Han; A W Partin; C R Pound; J I Epstein; P C Walsh
Journal:  Urol Clin North Am       Date:  2001-08       Impact factor: 2.241

5.  Who is the average patient presenting with prostate cancer?

Authors:  Kirsten L Greene; Janet E Cowan; Matthew R Cooperberg; Maxwell V Meng; Janeen DuChane; Peter R Carroll
Journal:  Urology       Date:  2005-11       Impact factor: 2.649

6.  Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2.

Authors:  Ai Tamura; Kanako Wakabayashi; Yuko Onishi; Misako Takeda; Yoji Ikegami; Seigo Sawada; Masahisa Tsuji; Yoichi Matsuda; Toshihisa Ishikawa
Journal:  Cancer Sci       Date:  2007-02       Impact factor: 6.716

7.  Functional analysis of SNPs variants of BCRP/ABCG2.

Authors:  Chihiro Kondo; Hiroshi Suzuki; Masaya Itoda; Shogo Ozawa; Jun-ichi Sawada; Daisuke Kobayashi; Ichiro Ieiri; Kazunori Mine; Kenji Ohtsubo; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

8.  Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules.

Authors:  Owen M Woodward; Deepali N Tukaye; Jinming Cui; Patrick Greenwell; Leeza M Constantoulakis; Benjamin S Parker; Anjana Rao; Michael Köttgen; Peter C Maloney; William B Guggino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

9.  Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.

Authors:  Owen M Woodward; Anna Köttgen; Josef Coresh; Eric Boerwinkle; William B Guggino; Michael Köttgen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-08       Impact factor: 11.205

10.  Real-time quantification of microRNAs by stem-loop RT-PCR.

Authors:  Caifu Chen; Dana A Ridzon; Adam J Broomer; Zhaohui Zhou; Danny H Lee; Julie T Nguyen; Maura Barbisin; Nan Lan Xu; Vikram R Mahuvakar; Mark R Andersen; Kai Qin Lao; Kenneth J Livak; Karl J Guegler
Journal:  Nucleic Acids Res       Date:  2005-11-27       Impact factor: 16.971

View more
  6 in total

1.  The contribution of ABCG2 G34A and C421A polymorphisms to multiple myeloma susceptibility.

Authors:  Katarzyna Niebudek; Ewa Balcerczak; Marek Mirowski; Jacek Pietrzak; Izabela Zawadzka; Marta Żebrowska-Nawrocka
Journal:  Onco Targets Ther       Date:  2019-02-27       Impact factor: 4.147

2.  Identification of key genes and specific pathways potentially involved in androgen-independent, mitoxantrone-resistant prostate cancer.

Authors:  Sha Zhu; Lili Jiang; Liuyan Wang; Lingli Wang; Cong Zhang; Yu Ma; Tao Huang
Journal:  Cancer Manag Res       Date:  2019-01-03       Impact factor: 3.989

Review 3.  Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation.

Authors:  Reka Varnai; Leena M Koskinen; Laura E Mäntylä; Istvan Szabo; Liesel M FitzGerald; Csilla Sipeky
Journal:  Genes (Basel)       Date:  2019-08-08       Impact factor: 4.096

4.  High expression of ABCG2 is associated with chemotherapy resistance of osteosarcoma.

Authors:  Hao Shu; Bin Yuan; Yao Huang; Lei Wang; Bing He; Qi Sun; Luning Sun
Journal:  J Orthop Surg Res       Date:  2021-01-28       Impact factor: 2.359

Review 5.  Medically Important Alterations in Transport Function and Trafficking of ABCG2.

Authors:  László Homolya
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

Review 6.  Picky ABCG5/G8 and promiscuous ABCG2 - a tale of fatty diets and drug toxicity.

Authors:  Narakorn Khunweeraphong; James Mitchell-White; Dániel Szöllősi; Toka Hussein; Karl Kuchler; Ian D Kerr; Thomas Stockner; Jyh-Yeuan Lee
Journal:  FEBS Lett       Date:  2020-10-14       Impact factor: 3.864

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.